Replies to post #357 on Oxford BioMedica PLC (OXBDF)

[marcusl2]

I didn`t see any mention of 5T4

Acknowledgments
We thank our colleagues at Novartis J Brogdon, P. Gotwals, S. Ettenberg and W. Sellers for insightful discussions and L. Johnson for primary cell lines.

Funding: This work was supported in part by grants from the National Institutes of Health (P01CA066726; 2R01CA120409) and by Novartis.